Supplementary Information

Orthogonal Assembly of a Designed Ankyrin Repeat Protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension

Manuel Simon†‡ƒ, Raphael Frey†¶, Uwe Zangemeister-Wittke†‡ and Andreas Plückthun†

M.S. and R. F. contributed equally to this work.

†Department of Biochemistry, Winterthurerstrasse 190, University of Zurich, CH-8057 Zurich, Switzerland
‡Institute of Pharmacology, Friedbühlstrasse 49, University of Bern, CH-3010 Bern, Switzerland
ƒCurrent address: Discovery Oncology, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
¶Current address: Laboratory of Organic Chemistry, ETH Hönggerberg, Zurich Switzerland

Corresponding authors:
Andreas Plückthun, Department of Biochemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland, E-mail: plueckthun@bioc.uzh.ch, Phone: +41-44-635-5570, Fax: +41-44-635-5712

or

Uwe Zangemeister-Wittke, Department of Biochemistry, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland and Institute of Pharmacology, University of Bern, Friedbühlstrasse 49, 3010 Bern, Switzerland. Phone: 41-31-632 3290; Fax: 41-31-632 4992; E-mail: uwe.zangemeister@pki.unibe.ch
SI Figure S1. SDS-PAGE (15%) analysis of clickable DARPin AzEc1c after expression in *E. coli* and IMAC purification. Protein conjugates were separated under reducing (Red.) or non-reducing (Non-Red.) conditions.
**SI Figure S2.** Detection of the quantitative conjugation of AzEc1c to mcMMAF by 22% SDS-PAGE. AzEc1c (at a concentration of 384 µM in PBS) was reacted with a 2-fold molar excess of mcMMAF and the crude reaction mixture was directly assessed by SDS-PAGE to detect the product AzEc1-MMAF and potential side products.
SI Figure S3. Elution profile of AzEc1-MMAF subjected to anion exchange chromatography for removal of unreacted DARPin AzEc1c.
**SI Figure S4.** Analysis of purified AzEc1-MMAF by SDS-PAGE (22%) and ESI-MS.
**SI Figure S5.** Cytotoxicity of the anti-EpCAM conjugate AzEc1-MMAF and the control conjugate AzOff7∆M-MMAF against EpCAM-positive HT29 cells. Cells were challenged with various concentrations of the conjugates for 3 days at 37°C before cell viability was determined in colorimetric cell viability assays (XTT). In the competition binding experiment, cells were incubated with saturating concentrations of DARPin Ec1 prior to addition of the conjugate. Each data point represents the mean of triplicates ± SD. All data, with the exception of the unmodified DARPin Ec1, were fitted by a non-linear regression curve (inhibitory dose response with a variable slope model provided by Prism 5, cf. eq 1 in the main manuscript). The table depicts the IC$_{50}$ values extrapolated from the fit. *n.d.* = no IC$_{50}$ value could be determined for unmodified Ec1 in the dose range tested.

<table>
<thead>
<tr>
<th></th>
<th>IC$_{50}$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ec1</td>
<td>n.d.</td>
</tr>
<tr>
<td>MMAF</td>
<td>6</td>
</tr>
<tr>
<td>AzEc1-MMAF</td>
<td>0.6</td>
</tr>
<tr>
<td>AzOff7∆M-MMAF</td>
<td>436</td>
</tr>
<tr>
<td>AzEc1-MMAF + 10× Ec1</td>
<td>231</td>
</tr>
</tbody>
</table>
SI Figure S6. Reaction kinetics of sulphydryl-activated MSA at 100 µM with 2.0 eq DBCO-PEG₄-Mal in PBS at 37°C. The conversion to DBCO-modified MSA was followed by RP-HPLC using the DBCO-specific absorption at 309 nm. Samples were taken from the reaction mixture after 5, 10, 15, 20 and 30 min, and the educt DBCO-PEG₄-Mal was subsequently quantified by RP-HPLC. A separate run of DBCO-PEG₄-Mal (at the starting concentration of 200 µM) was used to quantify the approximate equivalents reacted to form MSA-DBCO.
**SI Figure S7.** Determination of any hypothetical non-specific interaction of DBCO with serum albumin by RP-HPLC. To test whether an undesired maleimide-independent reaction of MSA with the DBCO core is possible, DBCO-NH$_2$ (missing a thiol-reactive maleimide) was added in different stoichiometries (0.5 - 3.0 eq) to MSA (100 µM in PBS) and incubated for 1 h at 37°C. (A) Chromatograms of RP-HPLC runs from each reaction mix detected with the DBCO-specific absorption at 309 nm. (B) Peak areas of non-reacted DBCO-NH$_2$ were plotted against the appropriate equivalents of DBCO-NH$_2$ used in the reaction and fitted by linear regression, indicating no significant reaction of the cyclooctyne DBCO with MSA at a concentration of 100 µM.
SI Figure S8. SDS-PAGE (4-12%) analysis of the SPAAC reaction between AzEc1-MMAF (189 µM) with MSA-DBCO (1.3 eq) after 72 h at 4°C.
**SI Figure S9.** Elution profiles from the purification of MSA-Ec1-MMAF by (A) anion exchange chromatography and (B) subsequent preparative gel filtration.
**SI Figure S10.** Mass determination of unmodified MSA by ESI-MS
SI Figure S11. Mass determination of purified MSA-Ec1-MMAF by ESI-MS.
**SI Figure S12.** Preparation of Alexa488-labeled conjugates used for cell-binding studies by flow cytometry. SDS-PAGE (10%) was used to monitor crude mixtures after reaction of (A) MSA-DBCO (80-90 μM) with 1.2 eq AzEc1-Alexa488 or with (B) 1.2 eq AzOff7ΔM-Alexa488 for 72 h at 4°C.
SI Figure S13. Chromatograms from (A, C) anion exchange and (B, D) preparative size exclusion chromatography runs for the purification of Alexa488-labeled conjugates for flow cytometry.
SI Figure S14. Analysis of purified MSA-Ec1-Alexa488 and MSA-Off7ΔM-Alexa488, and their building blocks by SDS-PAGE (4-12%).
**SI Figure S15.** Determination of association and dissociation rate constants of (A) unmodified DARPin Ec1, and the conjugates (B) AzEc1-MMAF and (C) MSA-Ec1-MMAF by surface plasmon resonance (ProteOn XPR36, Bio-Rad) using a NLC chip coated with the extracellular domain of human EpCAM (hEpEX).
**SI Figure S16.** Serum stability of MSA-Ec1-MMAF. The conjugate was diluted in non-heat activated mouse serum at a concentration of 1 µM and incubated at 37°C before aliquots were withdrawn at different time points. Samples were subjected to pull-down of His-tagged conjugates by magnetic Ni-NTA agarose beads, separated on SDS-PAGE and subsequently detected by Western blotting, using an anti-RGSHis₆-HRP Ab conjugate for direct detection of the N-terminal RGSHis-tag of DARPs.